

Title (en)
CLEAR CELL RENAL CELL CARCINOMA BIOMARKERS

Title (de)
KLARZELLIGE BIOMARKER FÜR NIERENZELLKARZINOM

Title (fr)
BIOMARQUEURS DU CARCINOME À CELLULES RÉNALES À CELLULES CLAIRES

Publication
EP 3679161 A4 20210602 (EN)

Application
EP 18854714 A 20180905

Priority
• SG 10201707218R A 20170905
• SG 2018050450 W 20180905

Abstract (en)
[origin: WO2019050478A1] Disclosed herein is a clear cell renal cell carcinoma (ccRCC) biomarker comprising at least 2 biomarkers selected from the group consisting of ZNF395, SMPDL3A, SLC28A1, SLC6A3, VEGFA, EGLN3, wherein at least one of the two biomarkers is SMPDL3A or SLC28A1. Also enclosed herein is a detection system using the biomarker set disclosed herein, methods of determining whether a subject has or shows recurrence of clear cell renal cell carcinoma, methods of determining whether a renal mass sample is benign or malignant, method of detecting response of a subject to systemic treatment, and a kit for carrying out the same.

IPC 8 full level
C12Q 1/6886 (2018.01); **G01N 33/574** (2006.01)

CPC (source: EP US)
C12Q 1/6886 (2013.01 - EP US); **G01N 33/57438** (2013.01 - EP US); **C12Q 2600/106** (2013.01 - US); **C12Q 2600/112** (2013.01 - US); **C12Q 2600/158** (2013.01 - EP US)

Citation (search report)
• [YA] WO 2017009084 A1 20170119 - AKURU PHARMA AB [SE]
• [YA] WO 2016156230 A1 20161006 - IMMATICS BIOTECHNOLOGIES GMBH [DE]
• [YA] WO 2014089055 A1 20140612 - AVEO PHARMACEUTICALS INC [US]
• [XAY] WO 2016004387 A1 20160107 - H LEE MOFFITT CANCER CT & RES [US]
• [XAY] WO 2015179773 A1 20151126 - SCRIPPS RESEARCH INST [US], et al
• [Y] WO 2017053192 A1 20170330 - UNIV TEXAS [US]
• [Y] MATHEW TRAINI ET AL: "Sphingomyelin Phosphodiesterase Acid-like 3A (SMPDL3A) Is a Novel Nucleotide Phosphodiesterase Regulated by Cholesterol in Human Macrophages", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 289, no. 47, 6 October 2014 (2014-10-06), pages 32895 - 32913, XP055581417, ISSN: 0021-9258, DOI: 10.1074/jbc.M114.612341
• [Y] KÁROLY TÓTH ET AL: "Constitutive Expression of HIF-[alpha] Plays a Major Role in Generation of Clear Cell Phenotype in Human Primary and Metastatic Renal Carcinoma NIH Public Access INTRODUCTION", APPL IMMUNOHISTOCHEM MOL MORPHOL, vol. 22, no. 9, 1 October 2014 (2014-10-01), pages 1 - 11, XP055676107, DOI: 10.1097/PAI.0000000000000012
• [Y] SARAH SCHRÖDTER ET AL: "Identification of the dopamine transporter SLC6A3 as a biomarker for patients with renal cell carcinoma", MOLECULAR CANCER, BIOMED CENTRAL, LONDON, GB, vol. 15, 1 February 2016 (2016-02-01), pages 1 - 10, XP002761862, ISSN: 1476-4598, DOI: 10.1186/S12943-016-0495-5
• [Y] STEFAN WINTER ET AL: "Methylomes of renal cell lines and tumors or metastases differ significantly with impact on pharmacogenes", SCIENTIFIC REPORTS, vol. 6, no. 1, 20 July 2016 (2016-07-20), XP055581422, DOI: 10.1038/srep29930
• [Y] S. COUVE ET AL: "Genetic Evidence of a Precisely Tuned Dysregulation in the Hypoxia Signaling Pathway during Oncogenesis", CANCER RESEARCH, vol. 74, no. 22, 15 November 2014 (2014-11-15), US, pages 6554 - 6564, XP055581426, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-14-1161
• [XP] XIAOSAI YAO ET AL: "VHL Deficiency Drives Enhancer Activation of Oncogenes in Clear Cell Renal Cell Carcinoma", CANCER DISCOVERY, vol. 7, no. 11, 11 September 2017 (2017-09-11), US, pages 1284 - 1305, XP055581446, ISSN: 2159-8274, DOI: 10.1158/2159-8290.CD-17-0375
• See also references of WO 2019050478A1

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)
WO 2019050478 A1 20190314; CN 111630183 A 20200904; CN 111630183 B 20240618; EP 3679161 A1 20200715; EP 3679161 A4 20210602; SG 11202002043Y A 20200429; US 2020347455 A1 20201105; US 2023279496 A1 20230907

DOCDB simple family (application)
SG 2018050450 W 20180905; CN 201880071330 A 20180905; EP 18854714 A 20180905; SG 11202002043Y A 20180905; US 201816642430 A 20180905; US 202217820925 A 20220819